Published papers
Academic conference presentation
Awards & honors
Education
Rsearch funding number
    （Last updated : 2026-06-25 09:55:01）
  ISHIHARA Hiroki
   Department   School of Medicine(Yachiyo Medical Center), School of Medicine  
   Position   Assistant Professor
■ Published papers
1. Original article　 Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
2. Original article　 Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
3. Case report　 Requiring caution in the interpretation of donor- derived cell- free DNA levels during cancer treatment in a kidney
transplant recipient.: A case report 2026/05
4. Original article　 Clinical evaluation of medical and surgical complete responses in metastatic renal cell carcinoma treated with immune checkpoint inhibitor combination therapy. 2026/04
5. Original article　 Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
Display all(125)
■ Academic conference presentation
1. Association of Serum Kidney Injury Molecule-1 with Treatment Response and Survival in Metastatic Renal Cell Carcinoma. （Speech，General） 2026/04/25
2. Multicenter study of polypharmacy and perioperative outcomes in robot-assisted laparoscopic radical cystectomy with intracorporeal urinary diversion (ICUD). （Poster notice，General） 2026/04/24
3. Real-world experience with adjuvant pembrolizumab toxicities in renal cell carcinoma: A single-center experience at Tokyo Women's Medical University. （Speech，General） 2026/04/24
4. Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （Poster notice，General） 2026/04/23
5. Mid-term real-world outcome of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs for renal cell carcinoma using minimum 3-year follow-up data. （Speech，General） 2026/04/23
Display all(55)
■ Awards & honors
1. 2016 The American Transplant Congress 2016 American Transplant Congress Best Poster Award (Evaluation of Microvascular Inflammation in ABO-incompatible Kidney Transplantation)
■ Education
1. 2017/04～2021/03 〔Doctoral course〕〔Doctorial Course〕, Tokyo Women's Medical University, Completed,
2. 2005/04～2011/03 Faculty of Medicine, Kanazawa University, Graduated
■ Rsearch funding number
20910821